The Experts below are selected from a list of 5610 Experts worldwide ranked by ideXlab platform

Jean-yves Blay - One of the best experts on this subject based on the ideXlab platform.

  • prediction of desmoid Tumor progression using mirna expression profiling
    Cancer Science, 2015
    Co-Authors: A Dufresne, Anne-valérie Decouvelaere, Marie Paturel, Laurent Alberti, Heloise Philippon, Philippe Cassier, Jean-yves Blay
    Abstract:

    Desmoid Tumor is a rare Connective Tissue Tumor with locoregional aggressiveness but unpredictable behavior. The miRNA profile was ascertained for 26 patients included in the Desminib phase II trial and an independent validation cohort of 15 patients. Predictive and prognostic supervised analysis on the Desminib cohort failed to identify miRNAs differentially expressed between progressive and non-progressive patients under imatinib treatment or between progressive and non-progressive patients after discontinuation of imatinib. However, an unsupervised hierarchical clustering of the Desminib cohort identified two groups (A and B) of 13 patients each, where only the number of previous lines of treatment before inclusion in the study differed significantly between the two groups. Time to progression after discontinuation of imatinib was longer in group B than in group A. Fifteen miRNAs were highly statistically differentially expressed between groups A and B, targeting more than 3000 genes, including AGO1, BCL2, CDK6, SMAD4, PTEN, CCND1, VEGFA, and RB1. These results were confirmed in the independent validation cohort: hierarchical clustering of these 15 miRNAs identified two groups, in which time to recurrence was statistically different (28.8 months vs 68.8 months). These results provide the first indication of the prognostic value of miRNA expression profiling with a possible direct impact on patient management. A more precise miRNA signature must now be determined to select patients who would not benefit from surgical resection of their Tumor and who ought to be monitored without treatment.

  • eight years Tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
    Clinical sarcoma research, 2015
    Co-Authors: Olivia Bally, Jean-yves Blay, Louis Tassy, Bertrand Richioud, Anne-valérie Decouvelaere, Olfa Derbel
    Abstract:

    Epithelioid hemangioendothelioma is a rare Connective Tissue Tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic Tumor to an aggressive rapidly growing neoplasm. Most Tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver Tumors and lung lesions. Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.

D. C. Harmon - One of the best experts on this subject based on the ideXlab platform.

  • Liposarcoma: a soft Tissue Tumor with many presentations
    MUSCULOSKELETAL SURGERY, 2014
    Co-Authors: H. J. Mankin, K. P. Mankin, D. C. Harmon
    Abstract:

    Liposarcoma is an uncommon Connective Tissue Tumor arising from lipoblast cells. The lesion is located in body soft parts and rarely arises from the bones. The Tumors are variable in presentation ranging from benign well-differentiated Tumors to myxoid and round cell-dedifferentiated and pleomorphic forms which can present with metastases. The lesions are most often treated by surgical resection. Chemotherapy and radiation may be added to the treatment of the more malignant variants with some success.

Anne-valérie Decouvelaere - One of the best experts on this subject based on the ideXlab platform.

  • prediction of desmoid Tumor progression using mirna expression profiling
    Cancer Science, 2015
    Co-Authors: A Dufresne, Anne-valérie Decouvelaere, Marie Paturel, Laurent Alberti, Heloise Philippon, Philippe Cassier, Jean-yves Blay
    Abstract:

    Desmoid Tumor is a rare Connective Tissue Tumor with locoregional aggressiveness but unpredictable behavior. The miRNA profile was ascertained for 26 patients included in the Desminib phase II trial and an independent validation cohort of 15 patients. Predictive and prognostic supervised analysis on the Desminib cohort failed to identify miRNAs differentially expressed between progressive and non-progressive patients under imatinib treatment or between progressive and non-progressive patients after discontinuation of imatinib. However, an unsupervised hierarchical clustering of the Desminib cohort identified two groups (A and B) of 13 patients each, where only the number of previous lines of treatment before inclusion in the study differed significantly between the two groups. Time to progression after discontinuation of imatinib was longer in group B than in group A. Fifteen miRNAs were highly statistically differentially expressed between groups A and B, targeting more than 3000 genes, including AGO1, BCL2, CDK6, SMAD4, PTEN, CCND1, VEGFA, and RB1. These results were confirmed in the independent validation cohort: hierarchical clustering of these 15 miRNAs identified two groups, in which time to recurrence was statistically different (28.8 months vs 68.8 months). These results provide the first indication of the prognostic value of miRNA expression profiling with a possible direct impact on patient management. A more precise miRNA signature must now be determined to select patients who would not benefit from surgical resection of their Tumor and who ought to be monitored without treatment.

  • eight years Tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
    Clinical sarcoma research, 2015
    Co-Authors: Olivia Bally, Jean-yves Blay, Louis Tassy, Bertrand Richioud, Anne-valérie Decouvelaere, Olfa Derbel
    Abstract:

    Epithelioid hemangioendothelioma is a rare Connective Tissue Tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic Tumor to an aggressive rapidly growing neoplasm. Most Tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver Tumors and lung lesions. Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.

Parish P Sedghizadeh - One of the best experts on this subject based on the ideXlab platform.

  • foreign body in the oral cavity mimicking a benign Connective Tissue Tumor
    Case Reports in Dentistry, 2013
    Co-Authors: Divya Puliyel, Amir Balouch, Saravanan Ram, Parish P Sedghizadeh
    Abstract:

    Foreign bodies may be embedded in the oral cavity either by traumatic injury or iatrogenically. The commonly encountered iatrogenic foreign bodies are restorative materials like amalgam, obturation materials, broken instruments, needles, and impression materials. This paper describes an asymptomatic presentation of a foreign body in the oral mucosa which clinically appeared like a benign Connective Tissue Tumor.

H. J. Mankin - One of the best experts on this subject based on the ideXlab platform.

  • Liposarcoma: a soft Tissue Tumor with many presentations
    MUSCULOSKELETAL SURGERY, 2014
    Co-Authors: H. J. Mankin, K. P. Mankin, D. C. Harmon
    Abstract:

    Liposarcoma is an uncommon Connective Tissue Tumor arising from lipoblast cells. The lesion is located in body soft parts and rarely arises from the bones. The Tumors are variable in presentation ranging from benign well-differentiated Tumors to myxoid and round cell-dedifferentiated and pleomorphic forms which can present with metastases. The lesions are most often treated by surgical resection. Chemotherapy and radiation may be added to the treatment of the more malignant variants with some success.